Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Merck & Co., Inc. stands seventh on our list and recently boosted Keytruda’s production.

Merck & Co., Inc. (NYSE:MRK), a global biopharmaceutical leader headquartered in Rahway, New Jersey, is renowned for its innovation in oncology, vaccines, and specialty medicines.

In June 2025, the FDA approved KEYTRUDA for perioperative use in adults with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) expressing PD-L1 (CPS ≥1). This marks the first approval of an anti-PD-1 therapy in the perioperative setting, allowing use both before and after surgery, combined with radiotherapy and as a standalone treatment. This milestone supports the company’s strategy to move immunotherapy into earlier stages of cancer care.

Merck & Co., Inc. (NYSE:MRK) is also expanding its oncology pipeline, sharing promising updates on KRAS G12C inhibitor MK-1084, zilovertamab vedotin, and sacituzumab tirumotecan, as well as new analyses of KEYTRUDA across over 25 cancer types.

Merck & Co., Inc. (MRK) Breaks Ground on $1B Biologics Hub to Boost KEYTRUDA Production

A pharmacist technician sorting pills in a drug pharmacy.

To meet growing demand and support biologics innovation, Merck & Co., Inc. (NYSE:MRK) began construction of a $1 billion Biologics Center of Excellence in Wilmington, Delaware, in April 2025. The 470,000-square-foot facility will focus on next-gen biologics and serve as the U.S. manufacturing hub for KEYTRUDA, bolstering supply chain resilience and production capacity.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.